David Lee Appointed Head Of Global Oncology For Shire
David K. Lee, Head, Global Oncology Franchise—David brings extensive expertise in pharmaceutical product development and growth to his new role. Prior to integrating with Shire, David worked as Director of Strategy and Operations for the oncology franchise at Baxalta where he focused on growing the group’s operations and portfolio. Previously, he held various leadership roles with Novartis including in regulatory strategy, government relations and overseeing the successful clinical trial execution and launch of novel products. Prior to Novartis, David worked as a life sciences management consultant to leading pharmaceutical companies. He received his medical degree at Harvard Medical School, an MBA from Harvard Business School, and a Bachelor’s of Science from Harvard College.
In his new role, David will lead Shire’s global oncology franchise, including marketing, business assessment and planning, and strategy for Shire’s oncology portfolio, which includes an approved product as well as investigational-stage candidates that address unmet needs for patients with rare and underserved cancers.
Jeff Hackman, Head, US Oncology Franchise—Jeff lends deep and broad experience in pharmaceutical operations, sales and marketing. He joins Shire from his previous position as Vice President and Region Head, North America at Baxalta, where he oversaw the commercial team from Sigma Tau Pharmaceuticals and established Baxalta’s first commercial presence in oncology with the purchase of the ONCASPAR (pegaspargase), for the treatment of acute lymphoblastic leukemia. Previously, with Sigma Tau Health Sciences, Jeff held positions including Chief Operating Officer and Board Member, and significantly grew the company’s oncology and rare disease franchises. Jeff has also held several leadership roles in market and sales with companies including Emergent BioSolutions, MedImmune and Aventis Pasteur, Inc.
In his new position, Jeff is responsible for the strategy and growth of the U.S. Oncology organization.
Peter Foertig, Global Head Oncology Franchise Medical Affairs—Peter brings significant experience in medical affairs to Shire, having previously worked as Head, Medical Affairs Oncology EMEA at Baxalta. Prior to Baxalta, Peter held roles in medical affairs with Amgen, including Medical Director International Medical Development as well as with the Schering-Plough Research Institute in Munich Germany as Head Medical Affairs Oncology/Immunology. Prior to his work in the pharmaceutical industry, Peter was a surgeon at the General Hospital of Aschaffenburg, Germany.
In his new role, Peter will lead medical affairs for the oncology franchise and portfolio development.
In his new role, David will lead Shire’s global oncology franchise, including marketing, business assessment and planning, and strategy for Shire’s oncology portfolio, which includes an approved product as well as investigational-stage candidates that address unmet needs for patients with rare and underserved cancers.
Jeff Hackman, Head, US Oncology Franchise—Jeff lends deep and broad experience in pharmaceutical operations, sales and marketing. He joins Shire from his previous position as Vice President and Region Head, North America at Baxalta, where he oversaw the commercial team from Sigma Tau Pharmaceuticals and established Baxalta’s first commercial presence in oncology with the purchase of the ONCASPAR (pegaspargase), for the treatment of acute lymphoblastic leukemia. Previously, with Sigma Tau Health Sciences, Jeff held positions including Chief Operating Officer and Board Member, and significantly grew the company’s oncology and rare disease franchises. Jeff has also held several leadership roles in market and sales with companies including Emergent BioSolutions, MedImmune and Aventis Pasteur, Inc.
In his new position, Jeff is responsible for the strategy and growth of the U.S. Oncology organization.
Peter Foertig, Global Head Oncology Franchise Medical Affairs—Peter brings significant experience in medical affairs to Shire, having previously worked as Head, Medical Affairs Oncology EMEA at Baxalta. Prior to Baxalta, Peter held roles in medical affairs with Amgen, including Medical Director International Medical Development as well as with the Schering-Plough Research Institute in Munich Germany as Head Medical Affairs Oncology/Immunology. Prior to his work in the pharmaceutical industry, Peter was a surgeon at the General Hospital of Aschaffenburg, Germany.
In his new role, Peter will lead medical affairs for the oncology franchise and portfolio development.